Close
28/05/2015
Synchrotron light applications for the pharmaceutical industry
More than forty people from the pharmaceutical sector attended the workshop organised by the ALBA Synchrotron on May 7.

Researchers from the MSPD, CLAESS, XALOC, NCD and MISTRAL ALBA beam lines have shown the available state-of-the-art techniques and the advantages that they offer in this field: fast data acquisition and shorter experiments, cost savings and, in the case of X-ray microscopy, suppression of ethical conflicts because this technique can be a previous step before clinical essays with animals and persons.

The companies Enantia and Almirall, which have already collaborated with the ALBA Synchrotron, have commented their own experiences at the facility. Enantia, specialised in research solutions for other companies, has detailed different examples. For Almirall, the analysis of polymorphic compounds – performed at ALBA – has increased its quality control, verifying and quantifying purity grades.

News based on the press release issued by the ALBA synchrotron.

Image: ALBA synchrotron. Structure of a herpesvirus nuclease-antiviral complex. Data collected at the Xaloc beam line (Bongarzone, S., Nadal, M. & Coll, M., IBMB)

More news

15/10/2020 Parc de l'Alba in a WHO project 02/10/2020 The hydraulic barrier of Can Planas comes into operation 30/09/2020 SENER, the leading urban transport engineering company in Mexico 16/09/2020 Biogas injected into the natural gas grid: works begin! 23/07/2020 Catalan start-ups know how to attract funding 06/07/2020 The Barcelona Synchrotron Park joins the new WEDISTRICT EU program
1 2 3 4 5 6 7 8 9